Nanome’s Post

Every month our team pulls together insights and perspectives on how drug discovery, intellectual property, and the field of data analytics intersect. We identify hot topics and biological targets worth discussion. Join the conversation by signing up for our newsletter. #seeIPdifferently #drugresearch #biopharma #IPalgorithm #biologicaltarget #drugdiscovery #dataanalytics #datavisualization

Attention Biopharma professionals! What's on the horizon for 2024? According to recent analysis, drug pricing remains the top factor impacting our industry. But that's not all. Other key factors include Generative AI, investment in innovation, and workforce and talent. At ZAETHER, we're committed to tackling these challenges head-on. While we may not be able to solve all the industry's problems, we're excited to be at the forefront of driving progress and innovation in Biopharma. #BiopharmaIndustry #DrugPricing #GenerativeAI #Innovation #WorkforceTalent #SupplyChains

Are we headed toward the Terminator or the Singularity? | #AI has been the hot topic of the year, and its safety is a frontier far beyond what we currently understand in healthcare. As a Life Sciences community, it's time for us to lead the conversation, focusing on AI's transformative potential rather than irrational fears. Join me, Ron Burns, at the Responsible AI in Clinical Trials Summit on October 8-9, 2024, where I'll share insights into how we can shape this global dialogue. 🔗 Register here: https://lnkd.in/e35wZ7d3 #AIinClinicalTrials #ResponsibleAI #AIinHealthcare #LifeSciences #ClinicalResearch #ClinicalTrials #Pharma #BioTech #MedTech

Accelerating Drug Discovery: IDM Insight's AI powered Solution to Research Roadblocks Powered by AI: IDM Insight Seamlessly integrates advanced algorithms and machine learning to accelerate drug discovery. Prioritize compounds and targets based on therapeutic potential and utilize our Generative AI tool for novel molecule design. Access over 2 million compounds, from preclinical to approved drugs, in one comprehensive platform. Our databases stand out with unmatched comprehensiveness, integrating data from diverse sources for confident decision-making. Dive into physico-chemical properties, bioactivities, and more, aiding rational drug design. Explore interconnected databases for a holistic view of biological pathways and disease mechanisms, supporting drug readdressing and repurposing campaigns. Read the full article to discover how IDM Insight is shaping the future of medicinal chemistry. #DrugDiscovery #MedicinalChemistry #AIIntegration #ResearchInnovation #IDMInsight #ScienceAdvancements

Excited to attend Bio-IT World this week, showcasing Unison's groundbreaking technology and engaging in discussions on #AI in #DrugDiscovery, #Bioinformatics platforms, #MultiModalData, and more. @ Unison, we've developed technology that enables rapid, seamless federation of disparate phenotype and molecular datasets, and that accelerates data harmonisation by up to 50%, ensuring interoperability while cutting costs and saving time. Example use cases: ⚡ Federating and interoperating across internal molecular and biobank data. ⚡ Federating and harmonising hospital record system data. ⚡ Federating and harmonising historical clinical trial data. We provide the infrastructure for our clients to maximise the value of their data through their bioinformatics research, while laying the foundation for developing the AI models of the future. PM me here to connect at Bio-IT World and to discuss how Unison can revolutionise your data management and analytics! #BioITWorld #DataFederation #DataHarmonisation #Interoperability.

🌟 Join us for the Drug Response Prediction track, at the AI in Drug Discovery Xchange, Boston. 🌟 🎟️ Secure your COMPLIMENTARY registration today! https://bit.ly/43qUJXC Our industry experts will delve into Drug Response Prediction with a focus AI to advance you further! 📈 👀 Here's a glimpse of what to expect: ✍🏽 Opening Address & Keynote Presentation by Optibrium 🗣️ Tasmin Mansley, Global Head of Application Science and President of US subsidiary, Optibrium ✍🏽 Enhancing drug response prediction using AI 🗣️ Wen-Han Yu, Associate Director, Computational Immunology, Moderna ✍🏽 Data quality topic: Computational best practices in data quality for AI/ML development. 🗣️ Simon Adar, Co-Founder and CEO, Code Ocean ✍🏽 Scaling ingestion and querying in omics data lakes 🗣️ Radhakrishna Bettadapura, Vice President, Business Development, Strand Life Sciences Don't miss out on this opportunity to network with industry peers and gain actionable insights to drive your business forward. Register now to secure your spot! 🤲🏽 🥇 With thanks to our Partners 🥇 Optibrium Biorelate Ltd. DrugBank Nostrum Biodiscovery Strand Life Sciences Code Ocean The Solubility Company Seqera Collaborative Drug Discovery - CDD Vault * Agenda subject to change 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 #AIinDrugDiscovery #DrugResponsePrediction #BostonEvents #HealthcareInnovation #DrugDiscoveryXchange #DataQualityAI #IndustryInsights #PharmaTech #AIinHealthcare #NetworkingEvent #DrugDevelopment #Bioinformatics #PrecisionMedicine #OmicsData #BiotechConference #LifeSciencesNetworking #hubXchange #Roundtable #FreePass #RegisterNow #ComplimenatryPass

Heading to #BioTechX EU 2024! I am particularly excited to explore the latest developments in AI for clinical research, LLMs in drug discovery, data integration and management, and the application of multi-omics and AI in precision medicine. If you are attending as well, let us connect and discuss! #BioTechX #PrecisionMedicine #AIClinicalResearch #MultiOmics #LLMDrugDiscovery #DataIntegration #HealthcareInnovation #Biotech #Networking

Elucidata was recognized as Fast Company's Most Innovative Company in the Biotech Category a couple of months ago. This recognition was (and is) a testament to our relentless pursuit of innovation and our commitment to pushing the boundaries of biotechnology. 🚀 At Elucidata, we leverage #datascience and #AI to accelerate drug discovery, streamline research processes, and unlock new insights into complex biological data. Our state-of-the-art data harmonization platform, Polly, transforms trillions of TBs of life sciences data into ML-Ready datasets, empowering researchers to achieve breakthroughs faster. ⚡⚡ Polly’s harmonization engine delivers curated biomolecular data, transforming them into a Unified Data Model that 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐬 𝐝𝐨𝐰𝐧𝐬𝐭𝐫𝐞𝐚𝐦 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐛𝐲 24𝐱 𝐰𝐢𝐭𝐡 99.99% 𝐚𝐜𝐜𝐮𝐫𝐚𝐜𝐲. Whether it’s pipeline development, #ML solutions, data visualization, or bioinformatic analysis, Polly is built to scale and meet the needs of leading biopharma players like Pfizer, Lilly, and Janssen. 🌐 This recognition from Fast Company not only reaffirms our leadership in biotech but also drives us to continue innovating for a healthier tomorrow. ⤴ Read more about us here- https://bit.ly/3SKsLSu

📣 NEWS: Announcing ReadCube Pro, an #AI-powered expansion of our award-winning ReadCube. Offering researchers new tools to simplify and accelerate literature management and literature monitoring workflows. Speaking at the AI in Drug Discovery Xchange event in San Francisco (hubXchange), ReadCube Co-founder and CEO Robert McGrath said: "Literature monitoring and literature review are critically important for life sciences organizations, yet in practice the work remains highly manual and involves multiple teams and tools. "These AI enhancements, along with a host of enhanced search and library features, are designed to radically streamline many common research workflows." Digital Science CEO Dr Daniel Hook said: "...for those in the fields of life sciences and pharmaceutical medicine, we believe that our tools can help to speed up discoveries that make a difference to health treatments and outcomes around the globe." 🔗 See their full comments in our announcement: https://ow.ly/FMH250TwctN 🔗 See more about ReadCube Pro: https://ow.ly/SUXb50TweXi #AIAssistant #LiteratureMonitoring #LiteratureManagement #LifeSciences #pharma #DrugDiscovery #PharmaSuccess #health #biotech #research #innovation

AI can be used in all aspects of drug development – from discovering biological targets, through developing chemical compounds, to conducting clinical trials. As we expected, this year at JP Morgan's Healthcare Conference, the AI theme was pervasive in almost every presentation, with key players presenting impressive new capabilities relevant to every stage of the value chain. Where does CytoReason fit into this growing trend? We use AI to model disease biology and drug effects. Our Computational Disease Models enable data integration across-the-board for decision making. The main goal is to help pharma enterprises improve probability of phase 2 success. Link to articles in comment below👇 #pharma #computationalbiology #biotech #drugdevelopment #jpm2024